We can gladly share the GU Ventures news – AMiLion Technology AB has been granted verification support from Almi to further develop its nanopore-based sensor for the detection of copper ions (Cu(II)). The sensor can measure extremely low levels – down to femtomolar concentration – in body fluids through precise electrical signals.

Why is this important? Elevated or altered levels of free copper ions in the blood are a critical biomarker in several serious diseases, including Wilson’s disease, Menkes disease, and in early diagnostics of Alzheimer’s disease. Direct measurement of bioavailable copper in serum or plasma can therefore become an entirely new tool for screening, diagnosis, and disease monitoring.

With the funding from Almi, AMiLion takes another step toward its vision: to transform advanced nanotechnology into practical tools that enable earlier and more effective healthcare.

About AMiLion Technology AB

AMiLion Technology AB was founded in 2021 by Dr. Alesia A. Tietze in collaboration with GU Ventures. The company develops a flexible technology platform for ultrasensitive diagnostics, initially focusing on metal-based biomarkers but which can be adapted for different types of analytes, such as proteins, for example antibodies.

Source link: https://www.guventures.com/news-all/2025/9/1/gu-ventures-bolag-amilion-technology-fr-verifieringsstd-frn-almi